Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Allergovit
Therapeutic Area : Otolaryngology (Ear, Nose, Throat)
Study Phase : Phase II
Sponsor : Inflamax Research
Deal Size : Inapplicable
Deal Type : Inapplicable
Evaluation of the Utility of an EEC for Assessing Efficacy of SIT in Pivotal Clinical Trials
Details : Allergovit is a Vaccine drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Rhinoconjunctivitis, Allergic.
Product Name : Undisclosed
Product Type : Vaccine
Upfront Cash : Inapplicable
November 21, 2014
Lead Product(s) : Allergovit
Therapeutic Area : Otolaryngology (Ear, Nose, Throat)
Highest Development Status : Phase II
Sponsor : Inflamax Research
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : rBet v1-FV
Therapeutic Area : Otolaryngology (Ear, Nose, Throat)
Study Phase : Phase II
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : RBet v1-FV is a drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Rhinoconjunctivitis, Allergic.
Product Name : Undisclosed
Product Type : Undisclosed
Upfront Cash : Inapplicable
December 13, 2011
Lead Product(s) : rBet v1-FV
Therapeutic Area : Otolaryngology (Ear, Nose, Throat)
Highest Development Status : Phase II
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Grass Pollen Allergen
Therapeutic Area : Otolaryngology (Ear, Nose, Throat)
Study Phase : Phase III
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
2nd Pivotal Study rPhleum - Adults and Adolescents With Rhinoconjunctivitis +/-Controlled Asthma
Details : RPhleum (Grass Pollen Allergen) is a Plant Extract/Herbal drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of Rhinoconjunctivitis, Allergic.
Product Name : rPhleum
Product Type : Plant Extract/Herbal
Upfront Cash : Inapplicable
May 16, 2011
Lead Product(s) : Grass Pollen Allergen
Therapeutic Area : Otolaryngology (Ear, Nose, Throat)
Highest Development Status : Phase III
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable